Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongmei Zuo

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Cancer Research|October 7, 2010
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune responseJosie Ursini-Siegel, Sean Cory, Dongmei Zuo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 22, 2017
Tongxie Formula Reduces Symptoms of Irritable Bowel SyndromeHeng Fan, Liang Zheng, Yaoliang Lai, et al.
Communications Biology|September 12, 2022
Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRα deficiencyCatherine R Dufour, Hui Xia, Wafa B'chir, et al.
Complementary Therapies in Medicine|April 28, 2022
Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: A randomized controlled trialYaoliang Lai, Xiao Liang, Heng Fan, et al.
Cell Reports|November 2, 2017
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast CancerPaul Savage, Alexis Blanchet-Cohen, Timothée Revil, et al.
Nature Communications|October 25, 2024
Osteopontin is a therapeutic target that drives breast cancer recurrenceYu Gu, Tarek Taifour, Tung Bui, et al.
The Journal of Clinical Investigation|February 16, 2023
Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progressionIpshita Nandi, Harvey W Smith, Virginie Sanguin-Gendreau, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2013
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancerJennifer F Knight, Robert Lesurf, Hong Zhao, et al.
JCI Insight|February 3, 2026
The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic disseminationTarek Taifour, Adéline Massé, Yu Gu, et al.
Complementary Therapies in Medicine|September 17, 2018
Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?-A randomized controlled trialYuanyuan Wang, Heng Fan, Xiao Qi, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Cancer Research|October 7, 2010
Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune responseJosie Ursini-Siegel, Sean Cory, Dongmei Zuo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 22, 2017
Tongxie Formula Reduces Symptoms of Irritable Bowel SyndromeHeng Fan, Liang Zheng, Yaoliang Lai, et al.
Communications Biology|September 12, 2022
Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRα deficiencyCatherine R Dufour, Hui Xia, Wafa B'chir, et al.
Complementary Therapies in Medicine|April 28, 2022
Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: A randomized controlled trialYaoliang Lai, Xiao Liang, Heng Fan, et al.
Cell Reports|November 2, 2017
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast CancerPaul Savage, Alexis Blanchet-Cohen, Timothée Revil, et al.
Nature Communications|October 25, 2024
Osteopontin is a therapeutic target that drives breast cancer recurrenceYu Gu, Tarek Taifour, Tung Bui, et al.
The Journal of Clinical Investigation|February 16, 2023
Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progressionIpshita Nandi, Harvey W Smith, Virginie Sanguin-Gendreau, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2013
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancerJennifer F Knight, Robert Lesurf, Hong Zhao, et al.
JCI Insight|February 3, 2026
The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic disseminationTarek Taifour, Adéline Massé, Yu Gu, et al.
Complementary Therapies in Medicine|September 17, 2018
Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?-A randomized controlled trialYuanyuan Wang, Heng Fan, Xiao Qi, et al.
Pageof 9